Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 16,800 shares, a drop of 11.1% from the January 15th total of 18,900 shares. Based on an average daily trading volume, of 6,200 shares, the short-interest ratio is presently 2.7 days.

Jasper Therapeutics Stock Down 8.5 %

Shares of NASDAQ:JSPRW traded down $0.01 during trading on Monday, reaching $0.15. The stock had a trading volume of 1,348 shares, compared to its average volume of 11,862. Jasper Therapeutics has a one year low of $0.09 and a one year high of $0.27. The firm’s 50-day simple moving average is $0.18 and its 200 day simple moving average is $0.20.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.